EUVIMEDEUVIMED entdecken
Multizentrische StudieStudienprotokollOpen Access · CC BY-NC 4.0

Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study

Aditi Bhatt iD, Snita Sinukumar iD, Dileep Damodaran iD, Loma Parikh iD, Gaurav Goswami iD, Sanket Mehta iD, Praveen Kammar iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e95 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Aditi Bhatt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India. aditimodi31@gmail.com. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Neoplasm Recurrence, Local, Ovarian Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The TORPEDO (CTRI/2018/12/016789) is the single-arm, prospective, interventional study evaluating the role of a total parietal peritonectomy (TPP) in patients undergoing interval cytoreductive surgery (iCRS). In this manuscript, we report the perioperative outcomes and platinum resistant recurrence (PRR) in 218 patients enrolled in the study. METHODS: A TPP was performed in all patients undergoing iCRS irrespective of the residual disease extent. hyperthermic intraperitoneal chemotherapy (HIPEC) was performed as per the clinician's discretion with 75 mg/m² of cisplatin. Maintenance therapy was also used at the discretion of the treating clinicians. RESULTS: From 9th December 2018 to 31st July 2022 (recruitment complete), 218 patients were enrolled at 4 medical centers in India. The median surgical peritoneal cancer index was 14 and a complete gross resection was achieved in 95.8%. HIPEC was performed in 130 (59.6%) patients. The 90-day major morbidity was 17.4% and 2.7% patients died within 90 days of surgery. Adjuvant chemotherapy was delayed beyond 6 weeks in 7.3%. At a median follow-up of 19 months (95% confidence interval [CI]=15.9-35 months), 101 (46.3%) recurrences and 19 (8.7%) deaths had occurred. The median progression-free survival was 22 months (95% CI=17-35 months) and the median overall survival (OS) not reached. Platinum resistant recurrence was observed in 6.4%. The projected 3-year OS was 81.5% and in 80 patients treated before may 2020, it was 77.5%. CONCLUSION: The morbidity and mortality of TPP with or without HIPEC performed during iCRS is acceptable. The incidence was of PRR is low. Early survival results are encouraging and warrant conduction of a randomized controlled trial comparing TPP with conventional surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytoreduction Surgical ProceduresNeoplasm Recurrence, LocalOvarian NeoplasmsDrug Resistance, NeoplasmPeritoneal NeoplasmsHumansFemaleMiddle AgedProspective StudiesAgedAdultHyperthermic Intraperitoneal ChemotherapyCisplatinChemotherapy, AdjuvantAntineoplastic AgentsTreatment OutcomePeritoneum

Stichwörter der Autor:innen

Cytoreductive SurgeryHIPECOvarian CancerOverall SurvivalProgression-Free Survival

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India. aditimodi31@gmail.com.
  • Department of Surgical Oncology, Jehangir Hospital, Pune, India.
  • Department of Surgical Oncology, MVR Cancer Center, Calicut, India.
  • Department of Pathology, Zydus Hospital, Ahmedabad, India.
  • Department of Radiology, Zydus Hospital, Ahmedabad, India.
  • Department of Surgical Oncology, Saifee Hospital, Mumbai, India.

ORCID-Profile: Aditi Bhatt, Snita Sinukumar, Dileep Damodaran, Loma Parikh, Gaurav Goswami, Sanket Mehta, Praveen Kammar

Zitieren

APA

Bhatt, A., Sinukumar, S., Damodaran, D., Parikh, L., Goswami, G., Mehta, S., & Kammar, P. (2024). Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e95

Vancouver

Bhatt A, Sinukumar S, Damodaran D, Parikh L, Goswami G, Mehta S, et al. Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e95

BibTeX
@article{Bhatt2024,
  author = {Bhatt, Aditi and Sinukumar, Snita and Damodaran, Dileep and Parikh, Loma and Goswami, Gaurav and Mehta, Sanket and Kammar, Praveen},
  title = {Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e95}
}
Kostenlos starten →